Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
01:20pm, Friday, 25'th Oct 2024
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
09:11am, Friday, 25'th Oct 2024
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
07:47am, Friday, 25'th Oct 2024
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the company's Dupixent drug, and more.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
07:18am, Friday, 25'th Oct 2024
On Friday, Sanofi SA SNY reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency.
Sanofi Q3 earnings beat market view, boosted by vaccine sales
01:32am, Friday, 25'th Oct 2024
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
08:00am, Thursday, 24'th Oct 2024
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved wel
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
12:35pm, Monday, 21'st Oct 2024
SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella.
French govt set to take stake in Sanofi unit after PE sale
03:06am, Monday, 21'st Oct 2024
France is reportedly set to acquire a small stake in Sanofi SA's (ADR) (NYSE:SNY) consumer healthcare unit as the pharmaceutical company proceeds with a €16 billion deal to sell half of the busine
Sanofi enters exclusive talks with CD&R for Opella sale
01:33am, Monday, 21'st Oct 2024
Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare
01:30am, Monday, 21'st Oct 2024
Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI
02:50pm, Sunday, 20'th Oct 2024
France will take a stake in Sanofi 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. priv
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
01:05pm, Thursday, 17'th Oct 2024
Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.
PAI Partners makes higher offer for Sanofi's Opella, says Le Monde
07:40am, Thursday, 17'th Oct 2024
French private equity firm PAI Partners has submitted a new, higher offer for Sanofi's consumer health business Opella, the Le Monde newspaper said on Thursday, as PAI seeks to outbid U.S. rival Clayt
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
01:30am, Thursday, 17'th Oct 2024
Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targete
